Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma
SE Finkelstein, T Carey, I Fricke, D Yu… - Journal of …, 2010 - journals.lww.com
Abstract High-dose intravenous interleukin-2 (IL-2) therapy (14 doses/course, 2
courses/cycle) for metastatic melanoma or kidney cancer induces infrequent, although major
responses. In this trial, we evaluated a new schedule (dose of 600,000 IU/kg, 8 h between
doses, 5 doses/course, 4 courses at weekly intervals/cycle) of high-dose IL-2, in which we
inserted more planned breaks while maintaining high cumulative dose delivery, and
investigated the relationship between dendritic cells (DC) and response to treatment. Target …
courses/cycle) for metastatic melanoma or kidney cancer induces infrequent, although major
responses. In this trial, we evaluated a new schedule (dose of 600,000 IU/kg, 8 h between
doses, 5 doses/course, 4 courses at weekly intervals/cycle) of high-dose IL-2, in which we
inserted more planned breaks while maintaining high cumulative dose delivery, and
investigated the relationship between dendritic cells (DC) and response to treatment. Target …